NantHealth Presents Research Demonstrating Real World Evidence of Simultaneous Presentation & Publication of Oncology Data at...
December 11 2019 - 06:00PM
Business Wire
Eviti Connect study showed an increase in
clinical uptake of practice-changing data
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
new breast cancer research findings presented during a poster
session at the San Antonio Breast Cancer Symposium (SABCS).
The Symposium, held at the Henry B. Gonzalez Convention Center
in San Antonio, TX from December 10-14, provides state-of-the-art
information on the experimental biology, etiology, prevention,
diagnosis and therapy of breast cancer and premalignant breast
disease, to an international audience of academic and private
physicians and researchers.
NantHealth’s presentation examined how results of the phase 3
KATHERINE clinical trial, first presented at SABCS 2018 and
simultaneously published in the New England Journal of Medicine
(NEJM), affected treatment patterns and regimen selections among
general medical oncologists in the U.S. before and after the
results were publicly released. Data from NantHealth’s Eviti
Connect, an evidence-based treatment intelligence and web-based
oncology decision support platform, was analyzed to determine the
rate of requests for treatment authorization for adjuvant
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive
early-stage breast cancer.
Study results indicated an immediate increase in T-DM1 use in
the months following SABCS 2018. Based on data pulled from Eviti
Connect, 95 cases would have received adjuvant T-DM1 in Q1 2019
after 0 in Q4 2018. When comparing T-DM1 and Trastuzumab use in the
adjuvant breast cancer setting for HER2-positive patients, T-DM1
use since December 2018 increased and Trastuzumab use decreased as
a percentage of treatment plan requests for adjuvant HER2-positive
patients.
“Our research clearly shows that presenting clinical data at a
leading conference like the San Antonio Breast Cancer Symposium,
and having the data simultaneously published in a medical journal,
influences a broad audience of oncologists,” said Sandeep “Bobby”
Reddy, MD, Chief Medical Officer, NantHealth. “As results indicate
an immediate increase in T-DM1 use in the months following SABCS
2018, leveraging multiple communications platforms is an important
and effective way to relay practice-changing clinical data to
practicing oncologists in the U.S. These forums and supporting
scientific journals expose researchers, academics and medical
professionals to the latest studies and ideas in the field for
which they can apply to their practice.”
Title: “Real world data on treatment patterns before and
after reporting of the KATHERINE trial: a phase 3 study of adjuvant
Ado-trastuzumab emtansine (T-DM1) versus trastuzumab in early stage
HER2+ breast cancer” Authors: Neil Margolis Ph.D., Vlad
Kozlovsky, William A. Flood MD, Sandeep K. Reddy MD Poster
Session and Number: Session 1, P1-15-08 Location: Henry
B. Gonzalez Convention Center Date and Time: Wednesday,
December 11, 2019 (5:00 PM – 7:00 PM CT)
“As cancer therapies become more complex, Eviti was designed to
help oncologists validate cancer treatment options and align all
parties around value-based oncological care. Defining the
appropriate regimens for patients is essential, and studies like
this are an effective way to communicate how medical meetings and
peer-reviewed journals are a valuable and timely way to get
information to physicians,” said Dr. William A. Flood, CMO of
Eviti.
About NantHealth: NantHealth, a member of the NantWorks
ecosystem of companies, provides leading solutions across the
continuum of care for physicians, payors, patients and
biopharmaceutical organizations. NantHealth enables the use of
cutting-edge data and technology toward the goals of empowering
clinical decision support and improving patient outcomes.
NantHealth’s comprehensive product portfolio combines the latest
technology in payor/provider platforms that exchange information in
near-real time (NaviNet and Eviti), connected care solutions that
deliver medical device interoperability (DCX device connectivity
platform and VCX patient vitals software) and molecular profiling
services that combine comprehensive DNA & RNA tumor-normal
profiling with pharmacogenomics analysis (GPS Cancer®). For more
information, please visit www.nanthealth.com or follow us on
Twitter, Facebook and LinkedIn.
Forward Looking Statement This news release contains
certain statements of a forward-looking nature relating to future
events or future business performance. Forward-looking statements
can be identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections,
and speak only as of the date they are made. Risks and
uncertainties include, but are not limited to: our ability to
successfully integrate a complex learning system to address a wide
range of healthcare issues; our ability to successfully amass the
requisite data to achieve maximum network effects; appropriately
allocating financial and human resources across a broad array of
product and service offerings; raising additional capital as
necessary to fund our operations; achieving significant commercial
market acceptance for our sequencing and molecular analysis
solutions; establish relationships with, key thought leaders or
payers’ key decision makers in order to establish GPS Cancer as a
standard of care for patients with cancer; our ability to grow the
market for our Systems Infrastructure, and applications;
successfully enhancing our Systems Infrastructure and applications
to achieve market acceptance and keep pace with technological
developments; customer concentration; competition; security
breaches; bandwidth limitations; our ability to continue our
relationship with NantOmics; our ability to obtain regulatory
approvals; dependence upon senior management; the need to comply
with and meet applicable laws and regulations; unexpected adverse
events; clinical adoption and market acceptance of GPS Cancer; and
anticipated cost savings. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors, many of which are discussed in more detail in
our reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191211005322/en/
NANT Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Feb 2024 to Mar 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2023 to Mar 2024